Takeda Acid Blocker Enters Phase III In Japan
This article was originally published in PharmAsia News
Executive Summary
Just four days after the commencement of a Phase III trial for TAK-875 for type 2 diabetes, Takeda Pharmaceutical said it has started a final stage domestic study for TAK-438